IP Library › Granted Patent US 12,227,568
Granted Patent B2
US 12,227,568 · App. 16/972,840 · Granted Feb 18, 2025

Anti-Siglec-7 antibodies and methods of use thereof

Inventors: Patricia Culp (Oakland, CA); Seung-Joo Lee (Benicia, CA); Helen Lam (Union City, CA); Wei-Hsien Ho (Belmont, CA); Arnon Rosenthal (Woodside, CA)
Assignee: ALECTOR LLC
C07K16/2803C07K2317/24C07K2317/31C07K2317/732C07K2317/734C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,227,568
App. No.
16/972,840
Granted
Feb 18, 2025
Kind
B2
Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Claims (48)

1. An antibody that binds to a Siglec-7 protein, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an HVR-H1, an HVR-H2, and an HVR-H3, and the light chain variable region comprises an HVR-L1, an HVR-L2, and an HVR-L3, wherein:

(a) the HVR-H1 comprises the amino acid sequence GYAFTMAWMN (SEQ ID NO: 2), the HVR-H2 comprises the amino acid sequence RIFPGYGHTN (SEQ ID NO: 8), the HVR-H3 comprises the amino acid sequence DYSDYYFDY (SEQ ID NO: 10), the HVR-L1 comprises the amino acid sequence RGSQDINTYLN (SEQ ID NO: 11), the HVR-L2 comprises the amino acid sequence YTSRLHS (SEQ ID NO: 16), and the HVR-L3 comprises the amino acid sequence QQGNLLPWT (SEQ ID NO: 17);

(b) the HVR-H1 comprises the amino acid sequence GYAFTGYWMN (SEQ ID NO: 3), the HVR-H2 comprises the amino acid sequence RIFPGLGHTN (SEQ ID NO: 7), the HVR-H3 comprises the amino acid sequence DYSDYYFDY (SEQ ID NO: 10), the HVR-L1 comprises the amino acid sequence RGSQDTNTYLN (SEQ ID NO: 12), the HVR-L2 comprises the amino acid sequence YTSRLHS (SEQ ID NO: 16), and the HVR-L3 comprises the amino acid sequence QQGNTLPWT (SEQ ID NO: 20);

(c) the HVR-H1 comprises the amino acid sequence GYAFTGYWMN (SEQ ID NO: 3), the HVR-H2 comprises the amino acid sequence RIFPGLGHTN (SEQ ID NO: 7), the HVR-H3 comprises the amino acid sequence DYSDYYFDY (SEQ ID NO: 10), the HVR-L1 comprises the amino acid sequence RGSQDINTYLN (SEQ ID NO: 11), the HVR-L2 comprises the amino acid sequence YTSRLHS (SEQ ID NO: 16), and the HVR-L3 comprises the amino acid sequence QQGNILPWT (SEQ ID NO: 23); or

(d) the HVR-H1 comprises the amino acid sequence GYAFTAAWMN (SEQ ID NO: 4), the HVR-H2 comprises the amino acid sequence RIFPGLGHTN (SEQ ID NO: 7), the HVR-H3 comprises the amino acid sequence DYSDYYFDY (SEQ ID NO: 10), the HVR-L1 comprises the amino acid sequence RGSQDINTYLN (SEQ ID NO: 11), the HVR-L2 comprises the amino acid sequence YTSRLHS (SEQ ID NO: 16), and the HVR-L3 comprises the amino acid sequence QQGNILPWT (SEQ ID NO: 23).

2. An antibody that binds to a Siglec-7 protein, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 41 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 52; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 42 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 55; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 42 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 60; or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 43 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 60.

3. The antibody of claim 1 , wherein the antibody is of the IgG class, the IgM class, or the IgA class.

4. The antibody of claim 3 , wherein the antibody is of the IgG class and has an IgG1, IgG2, IgG3, or IgG4 isotype.

5. The antibody of claim 4 , wherein:

(a) the Fc region comprises an amino acid substitution at position P331S, wherein the numbering of the residue position is according to EU numbering;

(b) the Fc region comprises an amino acid substitution at positions L234A, L235A, and P331S, wherein the numbering of the residue position is according to EU numbering;

(c) the Fc region comprises an amino acid substitution at position N297A, wherein the numbering of the residue position is according to EU numbering; or

(d) the Fc region comprises an amino acid substitution at positions S267E and L328F, wherein the numbering of the residue position is according to EU numbering.

6. The antibody of claim 1 , wherein the Siglec-7 protein is a non-human primate protein or a human protein.

7. The antibody of claim 1 , wherein the Siglec-7 protein is a wild-type protein.

8. The antibody of claim 1 , wherein the Siglec-7 protein is a naturally occurring variant.

9. The antibody of claim 1 , wherein the Siglec-7 protein is expressed on one or more cells selected from the group consisting of human dendritic cells, human macrophages, human monocytes, human osteoclasts, human neutrophils, human natural killer (NK) cells, human T cells, human T helper cell, human cytotoxic T cells, human granulocytes, and human microglia.

10. The antibody of claim 1 , wherein the antibody binds specifically to a human Siglec-7 protein.

11. The antibody of claim 1 , wherein the antibody is an antibody fragment that binds to an epitope comprising amino acid residues on a non-human primate Siglec-7 protein or a human Siglec-7 protein.

12. The antibody of claim 1 , wherein the antibody is an antibody fragment that binds to one or more human proteins selected from the group consisting of human Siglec-7, a naturally occurring variant of human Siglec-7, and a disease variant of human Siglec-7.

13. The antibody of claim 12 , wherein the antibody fragment is cross-linked to a second antibody fragment that binds to one or more human proteins selected from the group consisting of human Siglec-7, a naturally occurring variant of human Siglec-7, and a disease variant of human Siglec-7.

14. The antibody of claim 12 , wherein the antibody fragment is an Fab, Fab′, Fab′-SH, F (ab′)2, Fv, or scFv fragment.

15. The antibody of claim 1 , wherein the antibody is a humanized antibody, a bispecific antibody, a monoclonal antibody, a multivalent antibody, a conjugated antibody, or a chimeric antibody.

16. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.

17. The antibody of claim 1 , wherein the antibody is a bispecific antibody recognizing a first antigen and a second antigen.

18. The antibody of claim 17 , wherein the first antigen is Siglec-7 and the second antigen is:

(a) a ligand and/or a protein expressed on immune cells, wherein the ligand and/or the protein is selected from the group consisting of CD33, CD40, OX40, ICOS, CD28, CD137/4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, CD38, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR, LAG3, DR5, CD39, CD70, CD73, TREM1, TREM2, Siglec-5, Siglec-9, Siglec-11, SirpA, CD47, CSF1-receptor, and phosphatidylserine; or

(b) a protein, a lipid, a polysaccharide, or a glycolipid expressed on one or more tumor cells.

19. The antibody of claim 1 , wherein the antibody is used in combination with one or more antibodies that bind an immunomodulatory protein selected from the group consisting of: CD33, CD40, OX40, ICOS, CD28, CD137/4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, CD38, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR3, DR5, CD39, CD70, CD73, LAG3, TREM1, TREM2, Siglec-5, Siglec-9, Siglec-11, SirpA, CD47, CSF1-receptor, phosphatidylserine, disease-causing nucleic acids, antisense GGCCCC (G2C4) repeat-expansion RNA, and any combination thereof.

20. The antibody of claim 1 , wherein the antibody has a dissociation constant (K D ) for human Siglec-7 that is at least 4-fold lower than an anti-Siglec-7 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 61 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 62; or at least 1-fold lower than an anti-Siglec-7 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 38 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 50, wherein the K D is determined by BioLayer Interferometry.

21. The antibody of claim 1 , wherein the antibody has a dissociation constant (K D ) for human Siglec-7 that ranges from about 124 nM to about 1 pM, or less than about 1 pM, and wherein the K D is determined by BioLayer Interferometry.

22. The antibody of claim 1 , wherein the antibody reduces cell surface levels of Siglec-7.

23. The antibody of claim 22 , wherein the Siglec-7 is expressed on the surface of human dendritic cells.

24. The antibody of claim 22 , wherein the antibody reduces cell surface levels of Siglec-7 in vitro.

25. The antibody of claim 22 , wherein the antibody reduces cell surface levels of Siglec-7 in vitro with a half maximal effective concentration (EC 50 ) that is less than 150 pM, as measured by flow cytometry.

26. The antibody of claim 22 , wherein the antibody reduces cell surface levels of Siglec-7 in vitro with an EC 50 that is at least 50% lower than an anti-Siglec-7 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 61 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 62; or at least 10% lower than an anti-Siglec-7 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 38 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 50, as measured by flow cytometry.

27. The antibody of claim 22 , wherein cell surface levels of Siglec-7 are reduced to at least 20%.

28. The antibody of claim 27 , wherein the antibody is at least 4.2-fold more potent than an anti-Siglec-7 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 61 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 62; or at least 1.4-fold more potent than an anti-Siglec-7 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 38 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 50, as measured by flow cytometry.

29. An isolated nucleic acid comprising a nucleic acid sequence encoding the antibody of claim 1 .

30. A vector comprising the nucleic acid of claim 29 .

31. An isolated host cell comprising the vector of claim 30 .

32. A method of producing an antibody that binds to Siglec-7, comprising culturing the cell of claim 31 so that the antibody is produced.

33. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

34. The antibody of claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 41 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 52; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 42 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 55; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 42 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 60; or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 43 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 60.

35. The antibody of claim 1 , wherein the HVR-H1 comprises the amino acid sequence GYAFTMAWMN (SEQ ID NO: 2), the HVR-H2 comprises the amino acid sequence RIFPGYGHTN (SEQ ID NO: 8), the HVR-H3 comprises the amino acid sequence DYSDYYFDY (SEQ ID NO: 10), the HVR-L1 comprises the amino acid sequence RGSQDINTYLN (SEQ ID NO: 11), the HVR-L2 comprises the amino acid sequence YTSRLHS (SEQ ID NO: 16), and the HVR-L3 comprises the amino acid sequence QQGNLLPWT (SEQ ID NO: 17).

36. The antibody of claim 1 , wherein the HVR-H1 comprises the amino acid sequence GYAFTGYWMN (SEQ ID NO: 3), the HVR-H2 comprises the amino acid sequence RIFPGLGHTN (SEQ ID NO: 7), the HVR-H3 comprises the amino acid sequence DYSDYYFDY (SEQ ID NO: 10), the HVR-L1 comprises the amino acid sequence RGSQDTNTYLN (SEQ ID NO: 12), the HVR-L2 comprises the amino acid sequence YTSRLHS (SEQ ID NO: 16), and the HVR-L3 comprises the amino acid sequence QQGNTLPWT (SEQ ID NO: 20).

37. The antibody of claim 1 , wherein the HVR-H1 comprises the amino acid sequence GYAFTGYWMN (SEQ ID NO: 3), the HVR-H2 comprises the amino acid sequence RIFPGLGHTN (SEQ ID NO: 7), the HVR-H3 comprises the amino acid sequence DYSDYYFDY (SEQ ID NO: 10), the HVR-L1 comprises the amino acid sequence RGSQDINTYLN (SEQ ID NO: 11), the HVR-L2 comprises the amino acid sequence YTSRLHS (SEQ ID NO: 16), and the HVR-L3 comprises the amino acid sequence QQGNILPWT (SEQ ID NO: 23).

38. The antibody of claim 1 , wherein the HVR-H1 comprises the amino acid sequence GYAFTAAWMN (SEQ ID NO: 4), the HVR-H2 comprises the amino acid sequence RIFPGLGHTN (SEQ ID NO: 7), the HVR-H3 comprises the amino acid sequence DYSDYYFDY (SEQ ID NO: 10), the HVR-L1 comprises the amino acid sequence RGSQDINTYLN (SEQ ID NO: 11), the HVR-L2 comprises the amino acid sequence YTSRLHS (SEQ ID NO: 16), and the HVR-L3 comprises the amino acid sequence QQGNILPWT (SEQ ID NO: 23).

Assignments (2)
SECURITY INTEREST Recorded Nov 14, 2024
From: ALECTOR, INC.; ALECTOR LLC
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 069386/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2022
From: CULP, PATRICIA; LEE, SEUNG-JOO; LAM, HELEN; HO, WEI-HSIEN; ROSENTHAL, ARNON
To: ALECTOR LLC
Reel/Frame 061800/0261 →
Continuity (2)
Provisional Application 62682439 · Jun 8, 2018
Related Publication 20210246204A1 · Aug 12, 2021
References Cited (358)
US 4469863A · Ts'o et al. · 1984 [cited by applicant]
US 4657760A · Kung et al. · 1987 [cited by applicant]
US 4676980A · Segal et al. · 1987 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5206344A · Katre et al. · 1993 [cited by applicant]
US 5225212A · Martin et al. · 1993 [cited by applicant]
US 5229275A · Goroff et al. · 1993 [cited by applicant]
US 5536821A · Agrawal et al. · 1996 [cited by applicant]
US 5541306A · Agrawal et al. · 1996 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5567610A · Borrebaeck et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5571894A · Wels et al. · 1996 [cited by applicant]
US 5573905A · Lerner et al. · 1996 [cited by applicant]
US 5587458A · King et al. · 1996 [cited by applicant]
US 5591669A · Krimpenfort et al. · 1997 [cited by applicant]
US 5614622A · Iyer et al. · 1997 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5637683A · Usher et al. · 1997 [cited by applicant]
US 5637684A · Cook et al. · 1997 [cited by applicant]
US 5641870A · Rinderknecht et al. · 1997 [cited by applicant]
US 5648237A · Carter et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5700922A · Cook · 1997 [cited by applicant]
US 5717083A · Cook et al. · 1998 [cited by applicant]
US 5719262A · Buchardt et al. · 1998 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5739277A · Presta et al. · 1998 [cited by applicant]
US 5739308A · Kandimalla et al. · 1998 [cited by applicant]
US 5739314A · Roy et al. · 1998 [cited by applicant]
US 5773601A · Agrawal · 1998 [cited by applicant]
US 5789199A · Joly et al. · 1998 [cited by applicant]
US 5840523A · Simmons et al. · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 5886165A · Kandimalla et al. · 1999 [cited by applicant]
US 5929226A · Padmapriya et al. · 1999 [cited by applicant]
US 5955599A · Iyer et al. · 1999 [cited by applicant]
US 5959177A · Hein et al. · 1999 [cited by applicant]
US 5962674A · Iyer et al. · 1999 [cited by applicant]
US 5977296A · Nielsen et al. · 1999 [cited by applicant]
US 6040498A · Stomp et al. · 2000 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6117992A · Iyer · 2000 [cited by applicant]
US 6140482A · Iyer et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6417429B1 · Hein et al. · 2002 [cited by applicant]
US 6420548B1 · Vézina et al. · 2002 [cited by applicant]
US 6455308B1 · Freier · 2002 [cited by applicant]
US 6982321B2 · Winter · 2006 [cited by applicant]
US 7034121B2 · Carreno et al. · 2006 [cited by applicant]
US 7087409B2 · Barbas, III et al. · 2006 [cited by applicant]
US 7125978B1 · Vézina et al. · 2006 [cited by applicant]
US 8148498B2 · Chedid et al. · 2012 [cited by applicant]
US 8614299B2 · Baurin et al. · 2013 [cited by applicant]
US 8796427B2 · Spee et al. · 2014 [cited by applicant]
US 9732160B2 · Rohlff et al. · 2017 [cited by applicant]
US 9879083B2 · Okamura et al. · 2018 [cited by applicant]
US 10047167B2 · Demarest et al. · 2018 [cited by applicant]
US 10227408B2 · White et al. · 2019 [cited by applicant]
US 10590198B2 · Monroe et al. · 2020 [cited by applicant]
US 11390680B2 · Monroe et al. · 2022 [cited by applicant]
US 20070148167A1 · Strohl · 2007 [cited by applicant]
US 20090181855A1 · Vasquez et al. · 2009 [cited by applicant]
US 20100056386A1 · Vasquez et al. · 2010 [cited by applicant]
US 20100280227A1 · Ambrose et al. · 2010 [cited by applicant]
US 20170306014A1 · Cornen et al. · 2017 [cited by applicant]
US 20220411503A1 · Monroe et al. · 2022 [cited by applicant]
CN 106831989A · 2017 [cited by applicant]
EP 0308936B1 · 1994 [cited by applicant]
EP 0404097B1 · 1996 [cited by applicant]
JP 2003517482A · 2003 [cited by applicant]
JP 2017532025A · 2017 [cited by applicant]
JP 2018525999A · 2018 [cited by applicant]
WO WO198704462A1 · 1987 [cited by applicant]
WO WO199100360A1 · 1991 [cited by applicant]
WO WO199110741A1 · 1991 [cited by applicant]
WO WO199200373A1 · 1992 [cited by applicant]
WO WO199308829A1 · 1993 [cited by applicant]
WO WO199311161A1 · 1993 [cited by applicant]
WO WO199316185A2 · 1993 [cited by applicant]
WO WO199404690A1 · 1994 [cited by applicant]
WO WO199627011A1 · 1996 [cited by applicant]
WO WO199633735A1 · 1996 [cited by applicant]
WO WO199634096A1 · 1996 [cited by applicant]
WO WO199711971A1 · 1997 [cited by applicant]
WO WO199717852A1 · 1997 [cited by applicant]
WO WO199824893A2 · 1998 [cited by applicant]
WO WO199932619A1 · 1999 [cited by applicant]
WO WO199958572A1 · 1999 [cited by applicant]
WO WO200044895A1 · 2000 [cited by applicant]
WO WO200056746A2 · 2000 [cited by applicant]
WO WO200075372A1 · 2000 [cited by applicant]
WO WO200114398A1 · 2001 [cited by applicant]
WO WO200129058A1 · 2001 [cited by applicant]
WO WO200136646A1 · 2001 [cited by applicant]
WO WO200144808A2 · 2001 [cited by applicant]
WO WO200190193A1 · 2001 [cited by applicant]
WO WO2004042072A2 · 2004 [cited by applicant]
WO WO2005026209A2 · 2005 [cited by applicant]
WO WO2007106585A1 · 2007 [cited by applicant]
WO WO2008079246A2 · 2008 [cited by applicant]
WO WO2009036379A2 · 2009 [cited by applicant]
WO WO2010105256A1 · 2010 [cited by applicant]
WO WO2011038301A2 · 2011 [cited by applicant]
WO WO2012009568A2 · 2012 [cited by applicant]
WO WO2012045752A1 · 2012 [cited by applicant]
WO WO2015023752A1 · 2015 [cited by applicant]
WO WO2015089449A2 · 2015 [cited by applicant]
WO WO2016038064A1 · 2016 [cited by applicant]
WO WO2017040301A1 · 2017 [cited by applicant]
WO WO2018006034A1 · 2018 [cited by applicant]
WO WO2019140273A1 · 2019 [cited by applicant]
Janeway et al., Immunology Third Edition, Garland Publishing Inc. 1997, Chapter 3, Structure of the Antibody Molecule and Immunoglobulin Genes, pp. 3:1-3:11. (Year: 1997). [cited by examiner]
Chiu et al. Antibodies 2019, 8,55; 1-80. (Year: 2019). [cited by examiner]
Sela-Culang et al. Frontiers in Immunology, 2013, vol. 4, Article 302, pp. 1-13. (Year: 2013). [cited by examiner]
Alegre, M.-L. et al. (Jun. 1, 1994). “A Non-Activating “Humanized” Anti-cd3 Monoclonal Antibody Retains Immunosuppressive Properties in Vivo,” Transplantation 57(11):1537-1543. [cited by applicant]
Almagro, J.C. et al. (2008). “Humanization of Antibodies,” Frontiers in Bio-Science 13:1619-1633. [cited by applicant]
Alphey, M.S. et al. (Jan. 31, 2003). “High Resolution Crystal Structures of Siglec-7,” The Journal of Biological Chemistry 278(5):3372-3377. [cited by applicant]
Al-Shawi, R.et al. (2008). “Neurotoxic and Neurotrophic Roles of proNGF and the Receptor Sortilin in the Adult and Ageing Nervous System,” European Journal of Neuroscience 27:2103-2114. [cited by applicant]
Angal, S. et al. (1993). “A Single Amino Acid Substitution Abolishes the Heterogeneity Of Chimeric Mouse/Human (IgG4) Antibody,” Molecular Immunology 30(1):105-108. [cited by applicant]
Angata, T. et al. (Apr. 2000). “Siglec-7: A Sialic Acid-Binding Lectin of the Immunoglobulin Superfamily,” Glycobiology 10(4):431-438. [cited by applicant]
Ariga, T. et al. (Mar. 11, 2008). “Role of Ganglioside Metabolism in the Pathogenesis of Alzheimer's Disease—A Review,” J. Lipid Res. 49:1157-1175. [cited by applicant]
Armour, K.L. et al. (1999). “Recombinant Human IgG Molecules Lacking FcGamma Receptor Binding and Monocyte Triggering Activities,” Eur. J. Immunol. 29:2613-2624. [cited by applicant]
Armour, K.L. et al. (2003). “Differential Binding To Human Fcyriia and Fcyriib Receptors by Human IgG Wildtype and Mutant Antibodies,” Molecular Immunology 40:585-593. [cited by applicant]
Armour, K.L. et al. (Jun. 25-28, 2000). “Mutant IgG Lacking FcyRIII Binding and ADCC Activities,” The Haematology Journal, poster Session 1, Presented at the 5th Annual Meeting of the European Haematology Association, B… [cited by applicant]
Arnett, M.G. et al. (Dec. 5, 2007). “pro-NGF, Sortilin, and p75NTR: Potential Mediators of Injury-Induced Apoptosis in the Mouse Dorsal Root Ganglion,” Brain Research 1183:32-42, 18 pages. [cited by applicant]
Asquith, D.L. et al. (2009). “Animal Models of Rheumatoid Arthritis,” Eur. J. Immunol. 39:2040-2044. [cited by applicant]
Attrill, H. et al. (Oct. 27, 2006; e-published on Aug. 8, 2006). “Siglec-7 Undergoes a Major Conformational Change When Complexed with the α(2,8)-Disialylganglioside GT1b,” J. Biol. Chem. 281:32774-32783. [cited by applicant]
Avril, T. et al. (2005). “The Membrane-Proximal Immunoreceptor Tyrosine-Based Inhibitory Motif is Critical for the Inhibitory Signaling Mediated by Siglecs-7 and -9, CD33-Related Siglecs Expressed on Human Monocytes and… [cited by applicant]
Baca, M. et al. (1997). “Antibody Humanization Using Monovalent Phage Display,” The Journal of Biological Chemistry 272(16):10678-10684. [cited by applicant]
Barbas III, C.F. et al. (Apr. 1994). “In Vitro Evolution of A Neutralizing Human Antibody To Human Immunodeficiency Virus Type 1 To Enhance Affinity And Broaden Strain Cross-Reactivity,” Proc Nat. Acad. Sci. USA 91:3809… [cited by applicant]
Bartholomaeus, P. et al. (2014). “Cell Contact-Dependent Priming and Fe Interaction with CD32+ Immune Cells Contribute to the TGN1412-Triggered Cytokine Response,” The Journal of Immunology 192:2091-2098. [cited by applicant]
Bax, M. et al. (Dec. 15, 2007). “Dendritic Cell Maturation Results in Pronounced Changes in Glycan Expression Affecting Recognition by Siglecs and Galectins,” J. Immunol. 179(12):8216-8224. [cited by applicant]
Beattie, M.S. et al. (Oct. 24, 2002). “ProNGF Induces p75-Mediated Death of Oligodendrocytes following Spinal Cord Injury,” Neuron 36(3):375-386. [cited by applicant]
Beckman Coulter (2011). “IOTest Anti-p75 / AIRMI-PE PN A22330—50 tests—Liquid—20 L/test—Clone Z176”, Beckmann Coulter Catalogue pp. 1-2. [cited by applicant]
Bio-Rad (2004). “Datasheet: MCA5782GA Product Details Mouse Anti Human Siglec-7”, Online catalogue, pp. 1-3. [cited by applicant]
Boerner, P. et al. (1991). “Production Of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes,” Journal of Immunology 147(1):86-95. [cited by applicant]
Bolt, S. et al. (1993). “Generation Of A Humanized, Non-Mitogenic Cd3 Monoclonal Antibody Which Retains In Vitro Immunosuppressive Properties,” European Journal Immunol. 23:403-411. [cited by applicant]
Brehm, M.A. et al. (Apr. 2010). “Humanized Mouse Models to Study Human Diseases,” Curr Opin Endocrinol Diabetes Obes. 17(2):120-125. [cited by applicant]
Brennan, M. et al. (Jul. 5, 1985). “Preparation Of Bispecific Antibodies By Chemical Recombination Of Monoclonal Immunoglobulin G1 Fragments,” Science 229:81-83. [cited by applicant]
Bruggemann, M. et al. (1993). “Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals,” Year in Immunol. 7:33-40. [cited by applicant]
Calligé, M. et al. (Jun. 2005). “CSN5/Jab1 is Involved in Ligand-Dependent Degradation of Estrogen Receptor a by the Proteasome,” Mol. Cell Biol. 25(11):4349-4358. [cited by applicant]
Cantoni, C. et al. (Mar. 2015). “Trem2 Regulates Microglial Cell Activation In Response To Demyelination In Vivo,” Acta Neuropathol, 129(3):429-447, thirty three pages. [cited by applicant]
Canziani, G.A. et al. (2004). “Kinetic Screening of Antibodies From Crude Hybridoma Samples Using Biacore,” Analytical Biochemistry 325:301-307. [cited by applicant]
Cao, X. et al. (Sep. 2011). “Macrophage Polarization In The Maculae Of Age-Related Macular Degeneration: A Pilot Study,” Pathology International 61(9):528-535, fourteen pages. [cited by applicant]
Capel, P.J.A. et al. (1994). “Heterogeneity of Human IgG Fc Receptors,” Immunomethods 4:25-34. [cited by applicant]
Carter, P. et al. (Feb. 1992). “High Level [cited by applicant]
Carter, P. et al. (May 1992). “Humanization of an Anti-p185HER2 Antibody for Human Cancer Therapy,” Proc. Natl. Acad. Sci. USA 89:4285-4289. [cited by applicant]
Chang et al. (2002). “Retinal Degeneration Mutants In The Mouse,” Vision Research 42:517-525. [cited by applicant]
Chothia, C. et al. (1987). “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol, 196:901-917. [cited by applicant]
Chu, S.Y. et al. (2008; e-pub. Aug. 8, 2008). “Inhibition of B cell Receptor-Mediated Activation of Primary Human B Cells by Coengagement of CD19 and FcyRIIb with Fe-Engineered Antibodies,” Molecular Immunology 45:3926-… [cited by applicant]
Clackson, T. et al. (1991). “Making Antibody Fragments Using Phage Display Libraries,” Nature 352(15):624-628. [cited by applicant]
Cole, M.S. et al. (Aug. 27, 1999). “HuM291, A Humanized Anti-Cd3 Antibody is Immunosuppressive to T Cells While Exhibiting Reduced Mitogenicity in Vitro,” Transplantation 68(4):563-571. [cited by applicant]
Correale, C. et al. (Feb. 2013). “Bacterial Sensor Triggering Receptor Expressed on Myeloid Cells-2 Regulates the Mucosal Inflammatory Response,” Gastroenterology 144(2):346-356. [cited by applicant]
Crocker, P.R. et al. (Apr. 2007). “Siglecs and their Roles in the Immune System,” Nat Rev Immunol. 7(4):255-266. [cited by applicant]
Crocker, P.R. et al. (Apr. 2012; e-published on Feb. 21, 2012). “CD33-related Siglecs as Potential Modulators of Inflammatory Responses,” Ann. NY Acad. Sci. 1253:102-111. [cited by applicant]
Crocker, P.R. et al. (Jul. 1999). “Molecular Analysis of Sialoside Binding to Sialoadhesin by NMR and Site-Directed Mutagenesis,” Biochem J. 341(Pt. 2):355-361. [cited by applicant]
Crocker, P.R. et al. (Jun. 1, 2001). “Siglecs, Sialic Acids and Innate Immunity,” Trends Immunol. 22(6):337-342. [cited by applicant]
Cruts, M. et al. (2008, e-pub. Mar. 6, 2008). “Loss of Progranulin Function in Frontotemporal Lobar Degeneration,” Trends Genetics 24(4):186-194. [cited by applicant]
Cunningham, B.C. et al. (Jun. 2, 1989). “High-Resolution Epitope Mapping Of hGH-Receptor Interactions By Alanine-Scanning Mutagenesis,” Science 244:1081-1085. [cited by applicant]
Daëron, M. (1997). “FC Receptor Biology,” Annu. Rev. Immunol. 15:203-234. [cited by applicant]
Dall'Acqua, W.F. et al. (Aug. 18, 2006). “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn),” The Journal Of Biological Chemistry 281(33):23514-23524. [cited by applicant]
Daneman, R. et al. (Oct. 29, 2010). “The Mouse Blood-Brain Barrier Transcriptome: A New Resource for Understanding the Development and Function of Brain Endothelial Cells,” PLoS One 5(10):e13741, sixteen pages. [cited by applicant]
Davis, P.M. et al. (2007). “Abatacept Binds To The Fc Receptor Cd64 But Does Not Mediate Complement-Dependent Cytotoxicity Or Antibody-Dependent Cellular Cytotoxicity,” The Journal of Rheumatology 34(11):2204-2210. [cited by applicant]
De Haas, M. et al. (1995). “Fcγ Receptors of Phagocytes,” J. Lab. Clin. Med. 126(4):330-341. [cited by applicant]
Ducry, L. et al. (Jan. 2010; e-published on Sep. 21, 2009). “Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies,” Bioconjugate Chemistry 21(1):5-13. [cited by applicant]
Edwards, B.M. et al. (2003). “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS,” J. Mol. Biol. 334:103-118. [cited by applicant]
El-Danaf, R.N. et al. (Feb. 11, 2015). “Characteristic Patterns of Dendritic Remodeling in Early-Stage Glaucoma: Evidence from Genetically Identified Retinal Ganglion Cell Types,” The Journal of Neuroscience 35(6):2329-… [cited by applicant]
Estep, P. et al. (Mar.-Apr. 2013). “High Throughput Solution-Based Measurement Of Antibody-Antigen Affinity And Epitope Binning,” mAbs. 5(2):270-278. [cited by applicant]
Etemad, S. et al. (2012). “A Novel In Vitro Human Microglia Model: Characterization of Human Monocyte-Derived Microglia,” Journal of Neuroscience Methods 209:79-89. [cited by applicant]
Fahnestock, M. et al. (2001). “The Precursor Pro-Nerve Growth Factor Is the Predominant Form of Nerve Growth Factor in Brain and Is Increased in Alzheimer's Disease,” Molecular and Cellular Neuroscience 18:210-220. [cited by applicant]
Falco, M. et al. (1999; e-pub. Sep. 20, 1999). “Identification and Molecular Cloning of p75/AIRM1, A Novel Member of the Sialoadhesin Family That Functions as an Inhibitory Receptor in Human Natural Killer Cells,” J. Ex… [cited by applicant]
Fan, Y.-J. (2008). “Differential effects of Pro-BDNF on Sensory Neurons after Sciatic Nerve Transection in Neonatal Rats,” European Journal of Neuroscience 27:2380-2390. [cited by applicant]
Fasen, K. et al. (Feb. 2008; e-published on Dec. 19, 2007). “Ligand Binding Induces Cbl-Dependent EphB1 Receptor Degradation Through the Lysosomal Pathway,” Traffic 9(2):251-266. [cited by applicant]
Feldhaus, M.J. et al. (2004, e-pub. May 31, 2004). “Yeast Display of Antibody Fragments: A Discovery and Characterization Platform,” Journal of Immunological Methods 290:69-80. [cited by applicant]
Fellouse, F.A. et al. (Aug. 24, 2004). “Synthetic Antibodies from a Four-Amino-Acid Code: A Dominant Role for Tyrosine in Antigen Recognition,” PNAS 101(34):12467-12472. [cited by applicant]
Fishwild, D.M. et al. (Jul. 1996). “High-Avidity Human Iggκ Monoclonal Antibodies from a Novel Strain of Minilocus Transgenic Mice,” Nature Biotechnology 14:845-851. [cited by applicant]
Gabathuler, R. (2010, e-pub. Aug. 5, 2009). “Approaches to Transport Therapeutic Drugs across the Blood-Brain Barrier to Treat Brain Diseases,” Neurobiology of Disease 37:48-57. [cited by applicant]
Gawish, R. et al. (Apr. 2015; e.pub Dec. 4, 2014). “Triggering Receptor Expressed on Myeloid cells-2 Fine-Tunes Inflammatory Responses in Murine Gram-Negative Sepsis,” The FASEB Journal 29(4):1247-1257. [cited by applicant]
Gerngross, T.U. (Nov. 2004, e-pub. Nov. 4, 2004). “Advances in the Production of Human Therapeutic Proteins in Yeasts and Filamentous Fungi,” Nature Biotechnology 22(11):1409-1414. [cited by applicant]
Gieseke, F. et al. (2012). “Siglec-7 Tetramers Characterize B-Cell Subpopulations and Leukemic Blasts,” Eur. J. Immunology 42:2176-2186. [cited by applicant]
Graham, F.L. et al. (1977). “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,” Journal of General Virology 36:59-72. [cited by applicant]
Griffiths, A.D. et al. (1993). “Human Anti-Self Antibodies with High Specificity from Phage Display Libraries,” The EMBO Journal 12(2):725-734. [cited by applicant]
Gruber, M. et al. (1994). “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in [cited by applicant]
Gupta, N. et al. (2003). “Activated Microglia in Human Retinitis Pigmentosa, Late-Onset Retinal Degeneration, and Age-Related Macular Degeneration,” Experimental Eye Research 76(4):463-471. [cited by applicant]
Hamers-Casterman, C. et al. (Jun. 3, 1993). “Naturally Occurring Antibodies Devoid of Light Chains,” Nature 363:446-448. [cited by applicant]
Harrington, A.W. et al. (Apr. 20, 2004). “Secreted proNGF is a Pathophysiological Death-Inducing Ligand After Adult CNS Injury,” Proc. Natl. Acad. Sci USA 101(16):6226-6230. [cited by applicant]
Harris, W.J. (Nov. 1, 1995). “Therapeutic Monoclonals-Production of Humanized Monoclonal Antibodies for In Vivo Imaging and Therapy,” Biochem. Soc. Transactions 23(4):1035-1038. [cited by applicant]
Hawkins, R.E. et al. (1992). “Selection of Phage Antibodies by Binding Affinity: Mimicking Affinity Maturation,” Journal of Molecular Biology 226:889-896. [cited by applicant]
Hezareh, M. et al. (Dec. 2001). “Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1,” Journal of Virology vol. 75(24):12161-12168. [cited by applicant]
Holliger, P. et al. (Jul. 1993). ““Diabodies”: Small Bivalent and Bispecific Antibody Fragments,” Proceedings of the National Academy of Sciences 90:6444-6448. [cited by applicant]
Hongo, J.S. et al. (1995). “Development and Characterization of Murine Monoclonal Antibodies to the Latency-Associated Peptide of Transforming Growth Factor β1,” Hybridoma 14(3):253-260. [cited by applicant]
Hoogenboom, H.R. et al. (1992). “By-Passing Immunisation. Human Antibodies from Synthetic Repertoires of Germline Hh Gene Segments Rearranged in Vitro,” Journal of Molecular Biology 227:381-388. [cited by applicant]
Hudak, J.E. et al. (Jan. 2014; e-pub. Nov. 24, 2013). “Glycocalyx Engineering Reveals a Siglec-Based Mechanism For NK Cell Immunoevasion,” Nat Chem Biol. 10(1):69-75, 22 pages. [cited by applicant]
Humphrey, M.B. et al. (2006). “TREM2, a DAP12-Associated Receptor, Regulates Osteoclast Differentiation and Function,” J Bone Miner Res. 21(2):237-245. [cited by applicant]
Hurle, M.R. et al. (Aug. 1994). “Protein Engineering Techniques for Antibody Humanization,” Current Opinion in Biotechnology 5:428-433. [cited by applicant]
Hutchins, J.T. et al. (Dec. 1995). “Improved Biodistribution, Tumor Targeting, and Reduced Immunogenicity in Mice with a Gamma 4 Variant of Campath-IH,” Proc. Natl. Acad. Sci. 92:11980-11984. [cited by applicant]
Hutton, M. et al. (Jun. 18, 1998). “Association of Missense and 5′-Splice-Site Mutations in Tau with the Inherited Dementia FTDP-17,” Nature 393:702-705. [cited by applicant]
Ikehara, Y. et al. (Oct. 8, 2004; e-pub. Aug. 3, 2004). “Negative Regulation of T Cell Receptor Signaling by Siglec-7 (p70/AIRM) and Siglec-9,” J. Biol. Chem. 279(41):43117-43125. [cited by applicant]
Ito, M. et al. (2008). “NOD/Shi-scid IL2rγnull (NOG) Mice More Appropriate for Humanized Mouse Models,” Curr Top Microbiol Immunol. 324:53-76. [cited by applicant]
Ito, R. et al. (May 2012; e-published on Feb. 13, 2012). “Current Advances in Humanized Mouse Models,” Cellular & Molecular Immunology 9(3):208-214. [cited by applicant]
Jackson, J.R. et al. (Apr. 1, 1995). “In Vitro Antibody Maturation. Improvement of a High Affinity, Neutralizing Antibody against IL-1 Beta,” The Journal of Immunology 157(7):3310-3319. [cited by applicant]
Jakobovits, A. et al. (Mar. 18, 1993) “Germ-line Transmission and Expression of a Human-derived Yeast Artificial Chromosome,” Nature 362:255-258. [cited by applicant]
Jakobovits, A. et al. (Mar. 1993). “Analysis of Homozygous Mutant Chimeric Mice: Deletion of The Immunoglobulin Heavy-chain Joining Region Blocks B-Cell Development and Antibody Production,” Proceedings of the National … [cited by applicant]
Jandus, C. et al. (Apr. 2014). “Interactions Between Siglec-7/9 Receptors and Ligands Influence NK Cell-Dependent Tumor Immunosurveillance,” J. Clinical Invest. 124(4):1810-1820. [cited by applicant]
Jansen, P. et al. (Nov. 2007, e-pub. Oct. 14, 2007). “Roles for the Pro-Neurotrophin Receptor Sortilin in Neuronal Development, Aging and Brain Injury,” Nature Neuroscience 10(11):1449-1457. [cited by applicant]
Johnson, K.S. et al. (Aug. 1993). “Human antibody engineering: Current Opinion in Structural Biology,” Current Opinion in Structural Biology 3(4):564-571. [cited by applicant]
Jones, P.T. et al. (May 29, 1986). “Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse,” Nature 321:522-525. [cited by applicant]
Kawasaki, N. et al. (Aug. 15, 2014; e-published on Jul. 7, 2014). “Targeted Delivery of Mycobacterial Antigens to Human Dendritic Cells via Siglec-7 Induces Robust T Cell Activation,” The Journal of Immunology 193(4):15… [cited by applicant]
Kelm, S. et al. (1994). “Sialoadhesin, Myelin-Associated Glycoprotein and CD22 Define a New Family of Sialic Acid-Dependent Adhesion Molecules of the Immunoglobulin Superfamily,” Current Biology 4(11):965-972. [cited by applicant]
Kelm, S. et al. (Jan. 1, 1996). “The Sialoadhesins—A Family of Sialic Acid-Dependent Cellular Recognition Molecules Within the Immunoglobulin Superfamily”, Glycoconjugate Journal 13(6):913-926. [cited by applicant]
Kniep, B. et al. (Sep. 15, 1993). “CDw60 Glycolipid Antigens of Human Leukocytes: Structural Characterization and Cellular Distribution,” Blood 82(6):1776-1786. [cited by applicant]
Koga, T. et al. (Apr. 15, 2004). “Costimulatory Signals Mediated by the ITAM Motif Cooperate with RANKL for Bone Homeostasis,” Nature 428:758-763. [cited by applicant]
Köhler, G. et al. (Aug. 7, 1975). “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,” Nature 256:495-497. [cited by applicant]
Kostelny, S.A. et al. (Mar. 1, 1992). “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology 148(5):1547-1553. [cited by applicant]
Kozbor, D. et al. (Dec. 1984). “A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies,” The Journal of Immunology 133(6):3001-3005. [cited by applicant]
Laird, A.S. et al. (Oct. 13, 2010). “Progranulin is Neurotrophic in Vivo and Protects against a Mutant TDP-43 Induced Axonopathy,” PLOS One 5(10):e13368, seven pages. [cited by applicant]
Langer, R. (Sep. 28, 1990). “New Methods of Drug Delivery,” Science 249(4976):1527-1533. [cited by applicant]
Lartigue, J.D. (Jul. 5, 2012). “Antibody-Drug Conjugates: Guided Missiles Deployed Against Cancerous Cells,” OncLive located at <https://www.onclive.com/printer?url=/publications/oncology-live/2012/June-2012/antibody-dr… [cited by applicant]
Lazar, G.A. et al. (Mar. 14, 2006). “Engineered Antibody Fc variants with Enhanced Effector Function,” PNAS 103(11):4005-4010. [cited by applicant]
Lee, C.V. et al. (2004). “Bivalent Antibody Phage Display Mimics Natural Immunoglobulin,” Journal of Immunological Methods 284(1-2):119-132. [cited by applicant]
Lee, C.V. et al. (2004). “High-affinity Human Antibodies from Phage-displayed Synthetic Fab Libraries with a Single Framework Scaffold,” Journal of Molecular Biology 340:1073-1093. [cited by applicant]
Li, H. et al. (Feb. 2006). “Optimization of Humanized IgGs in Glycoengineered Pichia Pastoris,” Nature Biotechnology 24(2):210-215. [cited by applicant]
Li, J. et al. (Mar. 7, 2006). “Human Antibodies for Immunotherapy Development Generated via a Human B Cell Hybridoma Technology,” PNAS 103(10):3557-3562. [cited by applicant]
Lightle, S. et al. (Mar. 24, 2010; e-published on Jan. 29, 2010). “Mutations Within a Human Lgg2 Antibody Form Distinct and Homogeneous Disulfide Isomers but do not Affect Fc Gamma Receptor or C1q Binding,” Protein Scie… [cited by applicant]
Lipovsek, D. et al. (2004, e-pub. May 31, 2004). “In-vitro protein evolution by ribosome display and mRNA display,” Journal of Immunological Methods 290:51-67. [cited by applicant]
Lloyd, C. et al. (2009; e-pub. Oct. 29, 2008). “Modelling the Human Immune Response: Performance of a 10I I Human Antibody Repertoire Against a Broad Panel of Therapeutically Relevant Antigens,” Protein Eng. Design & Se… [cited by applicant]
Lock, K. et al. (Jan. 2004). “Expression of CD33-Related Siglecs on Human Mononuclear Phagocytes, Monocyte-Derived Dendritic Cells and Plasmacytoid Dendritic Cells,” Immunobiology 209(1-2):199-207. [cited by applicant]
Lonberg, N. et al. (1995). “Human Antibodies from Transgenic Mice,” International Reviews of Immunology. 13:65-93. [cited by applicant]
Lonberg, N. et al. (Apr. 28, 1994). “Antigen-Specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications,” Nature 368:856-859. [cited by applicant]
Low, D. et al. (2013). “Animal Models of Ulcerative Colitis and their Application in Drug Research,” Drug Design, Development and Therapy 7:1341-1357. [cited by applicant]
Lütje, S. et al. (Feb. 19, 2014). “Anti-CEA Antibody Fragments Labeled with [18F]AIF for PET Imaging of CEA-Expressing Tumors,” Bioconjugate Chemistry 25(2):335-341. [cited by applicant]
Macauley, M.S. et al. (Jan. 2014). “Glyco-Engineering ‘Super-Self’,” Nat. Chem. Biol. 10(1):7-8. [cited by applicant]
Macauley, M.S. et al. (Oct. 2014; e-published on Sep. 19, 2014). “Siglec Regulation of Immune Cell Function in Disease,” Nature Reviews Immunology 14(10):653-666, twenty nine pages. [cited by applicant]
Marks, J.D. et al. (1991). “By-passing immunization: Human antibodies from V-gene libraries displayed on phage,” Journal of Molecular Biology 222(3): 581-597. [cited by applicant]
Marks, J.D. et al. (Jul. 1992). “By-Passing Immunization: Building High Affinity Human Antibodies By Chain Shuffling,” Bio/Technology 10:779-782. [cited by applicant]
Martens, L.H. et al. (Nov. 2012). “Progranulin Deficiency Promotes Neuroinflammation and Neuron Loss Following Toxin-Induced Injury,” The Journal of Clinical Investigation 122(11):3955-3959. [cited by applicant]
Mather, J.P. (1980). “Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines,” Biology of Reproduction 23:243-252. [cited by applicant]
Mather, J.P. et al. (1982). “Culture of Testicular Cells in Hormone-Supplemented Serum-Free Medium,” Annals of the New York Academy of Sciences, Testicular Cell Culture 383:44-68. [cited by applicant]
May, A.P. et al. (Apr. 1998). “Crystal Structure of the N-Terminal Domain of Sialoadhesin in Complex with 3′ Sialyllactose at 1.85 Å Resolution,” Molecular Cell 1(5):719-728. [cited by applicant]
McCafferty, J. et al. (Dec. 6, 1990). “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains,” Nature 348:552-554. [cited by applicant]
McEarchern, J.A. et al. (Feb. 1, 2007, e-pub. Oct. 12, 2006). “Engineered Anti-CD70 Antibody with Multiple Effector Functions Exhibits in Vitro and in Vivo Antitumor Activities,” Blood 109(3):1185-1192. [cited by applicant]
McMillan, S.J. et al. (Aug. 11, 2008; e-published on Jan. 17, 2008). “CD33-related Sialic-Acid-Binding Immunoglobulin-Like Lectins in Health and Disease,” Carbohydrate Research 343(12):2050-2056. [cited by applicant]
McMillan, S.J. et al. (Mar. 14, 2013; e-pub. Jan. 11, 2013). “Siglec-E is a Negative Regulator of Acute Pulmonary Neutrophil Inflammation and Suppresses CD11b β2-Integrin-Dependent Signaling,” Blood 121(11):2084-2094. [cited by applicant]
Melchior, B. et al. (Jul. 12, 2010). “Dual Induction of TREM2 and Tolerance-Related Transcript, Tmem176b, in amyloid transgenic Mice: Implications for Vaccine-Based therapies for Alzheimer's Disease,” ASN Neuro 2(3) e00… [cited by applicant]
Milstein, C. et al. (Oct. 6, 1983). “Hybrid Hybridomas and their use in Immunohistochemistry,” Nature 305:537-540. [cited by applicant]
Mizoguchi, A. (2012). “Animal Models of Inflammatory Bowel Disease,” Progress in Molecular Biology and Translational Science 105:263-320, fifty eight pages. [cited by applicant]
Monsonego-Oran, E. et al. (Sep. 25, 2002; e-published on Aug. 28, 2002). “FGF Receptors Ubiquitylation: Dependence on Tyrosine Kinase Activity and Role in Downregulation,” FEBS Letters 528(1-3):83-89. [cited by applicant]
Morimoto, K. et al. (1992). “Single-Step Purification of F(ab′)2 Fragments of Mouse Monoclonal Antibodies (Immunoglobulins G1) by Hydrophobic Interaction High Performance Liquid Chromatography Using TSKgel Phenyl-5PW,” … [cited by applicant]
Morrison, S.L. (Apr. 28, 1994). “Success in Specification,” Nature 368:812-813. [cited by applicant]
Morrison, S.L. et al. (Nov. 1984). “Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains,” Proc. Nat'l Acad. Sci 81:6851-6855. [cited by applicant]
Munson, P.J. et al. (1980). “Ligand: A Versatile Computerized Approach for Characterization of Ligand-binding Systems,” Analytical Biochemistry 107:220-239. [cited by applicant]
Nakamura, K. et al. (2007).“Intracellular Sortilin Expression Pattern Regulates proNGF-Induced Naturally Occurring Cell Death during Development,” Cell Death and Differentiation 14:1552-1554. [cited by applicant]
Neary, D. et al. (Dec. 1998). “Frontotemporal Lobar Degeneration: A Consensus on Clinical Diagnostic Criteria,” Neurology 51:1546-1554. [cited by applicant]
Neuberger, M. (Jul. 1996). “Generating high-avidity human Mabs in mice,” Nature Biotechnology 14:826, one page. [cited by applicant]
Neumann, M. et al. (Oct. 2007). “TDP-43 Proteinopathy in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis,” Arch Neurol. 64(10):1388-1394. [cited by applicant]
Nicoll, G. et al. (2003). “Ganglioside GD3 Expression on Target Cells Can Modulate NK Cell Cytotoxicity Via Siglec-7-Dependent and -Independent Mechanisms,” Eur. J. Immunol. 33(6):1642-1648. [cited by applicant]
Nicoll, G. et al. (Nov. 26, 1999). “Identification and Characterization of a Novel Siglec, Siglec-7, Expressed by Human Natural Killer Cells and Monocytes,” The Journal of Biological Chemistry 274(48):34089-34095. [cited by applicant]
Novack, D.V. et al. (2008). “The Osteoclast: Friend or Foe?,” Annu. Rev. Pathol. Mech. Dis. 3:457-484. [cited by applicant]
Nykjaer, A. et al. (2005, e-pub. Jan. 26, 2005). “p75NTR—Live or Let Die,” Current Opinion in Neurobiology 15:49-57. [cited by applicant]
Nykjaer, A. et al. (Feb. 26, 2004). “Sortilin is Essential for proNGF Induced Neuronal Cell Death,” Nature 427:843-848. [cited by applicant]
Oganesyan, V. et al. (2008). “Structural characterization of a Human Fc Fragment Engineered for Lack of Effector Functions,” Acta Crystallography 64:700-704. [cited by applicant]
Ohgidani, M. et al. (May 14, 2014). “Direct induction of ramified microglia-like cells from human monocytes: Dynamic microglial dysfunction in Nasu-Hakola disease,” Scientific Reports 4(Article No. 4957):1-7. [cited by applicant]
Orr, S.J. et al. (Feb. 9, 2007). “SOCS3 Targets Siglec 7 for Proteasomal Degradation and Blocks Siglec 7-mediated Responses,” Journal of Biological Chemistry 282(6):3418-3422. [cited by applicant]
Otero, K. et al. (2012; e-published on Feb. 6, 2012). “TREM2 and β-Catenin Regulate Bone Homeostasis by Controlling the Rate of Osteoclastogenesis,” J Immunol188:2612-2621. [cited by applicant]
Park, M. et al. (Jan. 2015). “Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Promotes Adipogenesis and Diet-Induced Obesity,” Diabetes 64:117-127. [cited by applicant]
Paul, S.P. et al. (Jul. 15, 2000). “Myeloid Specific Human CD33 is an Inhibitory Receptor With Differential ITIM Function in Recruiting the Phosphatases SHP-1 and SHP-2,” Blood 96(2):483-490. [cited by applicant]
Peng, Q. et al. (May 18, 2010). “TREM2- and DAP12-Dependent Activation of PI3K Requires DAP10 and Is Inhibited by SHIP1,” Science Signaling 3(122):ra38, pp. 1-15. [cited by applicant]
Pennesi, M.E. et al. (Aug. 2012). “Animal Models of Age Related Macular Degeneration,” Molecular Aspects of Medicine 33(4):487-509, forty pages. [cited by applicant]
Peters, S.J. et al. (Jul. 13, 2012). “Engineering an Improved IgG4 Molecule with Reduced Disulfide Bond Heterogeneity and Increased Fab Domain Thermal Stability,” The Journal of Biological Chemistry 287(29):24525-24533. [cited by applicant]
Pillai, S. et al. (2012; Jan. 3, 2012). “Siglecs and Immune Regulation,” Annu. Rev. Immunol. 30:357-392. [cited by applicant]
Plückthun, A. (Dec. 1992). “Mono- and Bivalent Antibody Fragments Produced in [cited by applicant]
Pollenz, R.S. et al. (Dec. 1, 2006, e-pub. Aug. 25, 2006). “Ligand-Dependent and -Independent Degradation of the Human Aryl Hydrocarbon Receptor (hAHR) in Cell Culture Models,” Chemico-Biological Interactions 164(1-2):4… [cited by applicant]
Presta, L.G. (1992). “Antibody Engineering,” Current Opinion in Structural Biology 2:593-596. [cited by applicant]
Presta, L.G. et al. (Sep. 1, 1993). “Humanization of an Antibody Directed Against IgE,” The Journal of Immunology 151(5):2623-2632. [cited by applicant]
Product sheet for Human Siglec-7/CD328 Antibody, Monoclonal mouse IgG2B Clone #194212, R&D Systems, Catalog No. MAB1138, Feb. 7, 2018. (Year: 2018). [cited by applicant]
Provenzano, M.J. (2008). “p75NTR and Sortilin Increase After Facial Nerve Injury,” Laryngoscope 118:87-93. [cited by applicant]
Ratnavalli, E. et al. (Jun. 2002). “The Prevalence of Frontotemporal Dementia,” Neurology 58(1 of 2):1615-1621. [cited by applicant]
Ravetch, J.V. et al. (1991). “Fc Receptors,” Annual Review Immunology 9:457-492. [cited by applicant]
Reddy, M.P. et al. (2000). “Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4,” The Journal of Immunology 164:1925-1933. [cited by applicant]
Reverberi, R. et al. (2007). “Factors Affecting the Antigen-Antibody Reaction,” Blood Transfus 5:227-240. [cited by applicant]
Riechmann, L. et al. (Mar. 24, 1988). “Reshaping Human Antibodies for Therapy,” Nature 332:323-327. [cited by applicant]
Roberts, R.W. et al. (Nov. 1997). “RNA-Peptide Fusions for the In Vitro Selection of Peptides and Proteins,” Proc. Natl. Acad. Sci. USA 94:12297-12302. [cited by applicant]
Rosok, M.J. et al. (Sep. 13, 1996). “Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab,” The Journal of Biological Chemistry 271(37):22611-22618. [cited by applicant]
Sazinsky, S.L. et al. (Dec. 23, 2008). “Aglycosylated Immunoglobulin G1 Variants Productively Engage Activating Fc Receptors,” PNAS 105(51):20167-20172. [cited by applicant]
Schabbauer, G. et al. (Jul. 2010). “Myeloid PTEN Promotes Inflammation but Impairs Bactericidal Activities During Murine Pneumococcal Pneumonia,” The Journal of Immunology 185(1):468-476. [cited by applicant]
Schaffitzel, C. et al. (1999). “Ribosome Display: An In Vitro Method for Selection and Evolution of Antibodies from Libraries,” Journal of Immunological Methods 231:119-135. [cited by applicant]
Schier, R. et al. (1996). “Identification of Functional and Structural Amino-Acid Residues by Parsimonious Mutagenesis,” Gene 169:147-155. [cited by applicant]
Schymick, J.C. et al. (2007). “Progranulin Mutations and Amyotrophic Lateral Sclerosis or Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Phenotypes,” Journal of Neurology, Neurosurgery and Psychiatry 78:754-756. [cited by applicant]
Seno, H. et al. (Jan. 6, 2009). “Efficient Colonic Mucosal Wound Repair Requires Trem2 Signaling,” PNAS 106(1):256-261. [cited by applicant]
Shalaby, M.F. et al. (Jan. 1992). “Development of Humanized Bispecitic Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene,” The Journal of Experimental Medicine 175:217-… [cited by applicant]
Sharif, O. et al. (Jun. 12, 2014). “The Triggering Receptor Expressed on Myeloid Cells 2 Inhibits Complement Component 1 q Effector Mechanisms and Exerts Detrimental Effects during Pneumococcal Pneumonia,” PLoS Pathogen… [cited by applicant]
Sheriff, S. et al. (Sep. 1996). “Redefining the Minimal Antigen-binding Fragment,” Nature Structural & Molecular Biology 3(9):733-736. [cited by applicant]
Shields, R.L. et al. (Mar. 2, 2001). “High Resolution Mapping of the Binding Site on Human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcyR,” The Journal Of Biologi… [cited by applicant]
Sidhu, S.S. et al. (Apr. 2004). “Phage-displayed Antibody Libraries of Synthetic Heavy Chain Complementarity Determining Regions,” Journal of Molecular Biology 338(2):299-310. [cited by applicant]
Sieber, M.W. et al. (Jan. 3, 2013). “Attenuated Inflammatory Response in Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Knock-Out Mice following Stroke,” PLoS One 8(1):e52982, ten pages. [cited by applicant]
Sims, M.J. et al. (Aug. 15, 1993). “A Humanized CD18 Antibody Can Block Function Without Cell Destruction,” The Journal of Immunology 151(4):2296-2308. [cited by applicant]
Siolas, D. et al. (Sep. 2013). “Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models,” Cancer Research 73(17):5315-5319. [cited by applicant]
Skerra, A. (1993). “Bacterial Expression of Immunoglobulin Fragments,” Current Opinion in Immunology 5:256-262. [cited by applicant]
Sollid, L.M. et al. (Sep. 2008). “Animal Models of Inflammatory Bowel Disease at the Dawn of the New Genetics Era,” PLoS Med 5(9):1338-1342(e198). [cited by applicant]
Strohl, W.R. (2009; e-published on Nov. 4, 2009). “Optimization of Fc-mediated Effector Functions of Monoclonal Antibodies,” Current Opinion in Biotechnology 20:685-691. [cited by applicant]
Sun, M. et al. (May 2013). “TREM-2 Promotes Host Resistance Against Pseudomonas aeruginosa Infection by Suppressing Corneal Inflammation via a PI3K/Akt Signaling Pathway,” Investigative Ophthalmology & Visual Science 54… [cited by applicant]
Suresh, M.R. et al. (1986). “Bispecific Monoclonal Antibodies from Hybrid Hybridomas,” Methods In Enzymology 121:210-228. [cited by applicant]
Svennerholm, L. (1964). “The Gangliosides,” J. Lipid Res. 5:145-155. [cited by applicant]
Takahashi, K. et al. (Apr. 10, 2007). “TREM2-Transduced Myeloid Precursors Mediate Nervous Tissue Debris Clearance and Facilitate Recovery in an Animal Model of Multiple Sclerosis,” Plos Med 4(4):e124, pp. 0675-0689. [cited by applicant]
Takahashi, K. et al. (Feb. 21, 2005). “Clearance of Apoptotic Neurons Without Inflammation by Microglial Triggering Receptor Expressed on Myeloid Cells-2,” Journal of Experimental Medicine 201(4):647-657. [cited by applicant]
Tanaka, Y. et al. (2013). “Exacerbated Inflammatory Responses Related To Activated Microglia After Traumatic Brain Injury In Progranulin-Deficient Mice,” Neuroscience 231:49-60. [cited by applicant]
Tavaré, R. et al. (Jan. 21, 2014). “Engineered Antibody Fragments for Immuno-PET Imaging of Endogenous CD8+ T Cells in Vivo,” PNAS 111(3):1108-1113. [cited by applicant]
Teng, H.K. et al. (Jun. 1, 2005). “ProBDNF Induces Neuronal Apoptosis via Activation of a Receptor Complex of p75 NTR and Sortilin,” The Journal of Neuroscience 25(22):5455-5463. [cited by applicant]
Traunecker, A. et al. (1991). “Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells,” The EMBO Journal 10(12):3655-3659. [cited by applicant]
Tutt, A. et al. (Jul. 1, 1991). “Trispecific F(ab′)3 Derivatives that Use Cooperative Signaling Via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells1,” The Journal of Immunology 147(1):60-6… [cited by applicant]
Ulyanova, T. et al. (1999). “The Sialoadhesin CD33 is a Myeloid-Specific Inhibitory Receptor,” Eur J Immunol. 29:3440-3449. [cited by applicant]
Urlaub, G. et al. (Jul. 1980). “Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity,” Proc. Natl. Acad. Sci. 77(7):4216-4220. [cited by applicant]
Urmacher, C .et al. (Dec. 1989). “Tissue Distribution of GD3 Ganglioside Detected by Mouse Monoclonal Antibody R24,” Am. J. Dermatopathol. 11(6):577-581. [cited by applicant]
Vafa, O. et al. (2014; e-published on Jul. 17, 2013). “An Engineered Fc Variant of an IgG Eliminates All Immune Effector Functions via Structural Perturbations,” Methods 65:114-126. [cited by applicant]
Van Dijk, M.A et al. (2001). “Human Antibodies as Next Generation Therapeutics,” Current Opinion in Chemical Biology 5:368-374. [cited by applicant]
Varchetta, S. et al. (Dec. 13, 2013). “Sialic Acid-Binding Ig-Like Lectin-7 Interacts with HIV-1 Gp120 and Facilitates Infection of CD4pos T Cells and Macrophages,” Retrovirology 10(1):154, pp. 1-13. [cited by applicant]
Varchetta, S. et al. (Sep. 28, 2012). “Engagement of Siglec-7 Receptor Induces a Pro-Inflammatory Response Selectively in Monocytes,” PLOS One 7(9):e45821, pp. 1-12. [cited by applicant]
Varki, A. et al. (Jan. 1, 2006; e-published on Jul. 13, 2005). “Siglecs-The Major Subfamily of I-Type Lectins,” Glycobiology 16(1):1R-27R. [cited by applicant]
Vaswani, S.K. et al. (Aug. 1998). “Humanized Antibodies as Potential Therapeutic Drugs,” Annals of Allergy, Asthma & Immunology 81:105-119. [cited by applicant]
Verhoeyen, M. et al. (1988). “Reshaping Human Antibodies: Grafting an Antilysozyme Activity,” Science 239:1534-1536. [cited by applicant]
Vetrano, S. et al. (2008). “Unique Role of Junctional Adhesion Molecule-A in Maintaining Mucosal Homeostasis in Inflammatory Bowel Disease,” Gastroenterology 135(1):173-184. [cited by applicant]
Vincent, K.J. et al. (Dec. 2012; e-pub. Nov. 1, 2012). “Current Strategies in Antibody Engineering: Fc Engineering and pH-dependent Antigen Binding, Bispecific Antibodies And Antibody Drug Conjugates,” Biotechnol J. 7(1… [cited by applicant]
Vitale, C. et al. (Dec. 21, 1999). “Engagement of p75/AIRM1 or CD33 Inhibits the Proliferation of Normal or Leukemic Myeloid Cells,” Proceedings Of The National Academy Of Sciences, USA 96(26):15091-15096. [cited by applicant]
Vitale, C. et al. (May 8, 2001). “Surface Expression and Function of P75/AIRM-1 or CD33 in Acute Myeloid Leukemias: Engagement of CD33 Induces Apoptosis of Leukemic Cells,” Proc Natl Acad Sci USA 98(10):5764-5769. [cited by applicant]
Volosin, M. et al. (Jul. 19, 2006). “Interaction of Survival and Death Signaling in Basal Forebrain Neurons: Roles of Neurotrophins and Proneurotrophins,” The Journal of Neuroscience 26(29):7756-7766. [cited by applicant]
Volosin, M. et al. (Sep. 24, 2008). “Induction of Proneurotrophins and Activation of P75ntr-Mediated Apoptosis Via Neurotrophin Receptor-Interacting Factor in Hippocampal Neurons After Seizures,” The Journal of Neurosci… [cited by applicant]
Von Gunten, S. et al. (Nov. 2008). “Basic and Clinical Immunology of Siglecs,” Ann. NY Acad. Sci. 1143:61-82, twenty five pages. [cited by applicant]
Wang, Y. et al. (Mar. 12, 2015; e-published on Feb. 26, 2015). “TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer's Disease Model,” Cell 160(6):1061-1071. [cited by applicant]
Waterhouse, P. et al. (1993). “Combinatorial Infection and In Vivo Recombination: A Strategy for Making Large Phage Antibody Repertoires,” Nucleic Acids Research 21(9):2265-2266. [cited by applicant]
Wei, Y. et al. (2007). “Enhanced Protein Expressions of Sortilin and p75NTR in Retina of Rat Following Elevated Intraocular Pressure-Induced Retinal Ischemia,” Neuroscience Letters 429(2-3):169-174. [cited by applicant]
White, A.L. et al. (Jan. 12, 2015). “Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies,” Cancer Cell 27:138-148. [cited by applicant]
Wiehr, S. et al. (2014). “Pharmacokinetics and PET Imaging Properties of Two Recombinant Anti-PSMA Antibody Fragments in Comparison to their Parental Antibody,” The Prostate 74(7):743-755. [cited by applicant]
Wilkinson, I.C. et al. (2013). “Monovalent IgG4 Molecules: Immunoglobulin Fc Mutations that Result in a Monomeric Structure,” mAbs 5(3):406-417. [cited by applicant]
Williams, J.J.L. et al. (2012). “Unbiased identification of substrates for the Epac1-inducible E3 ubiquitin ligase component SOCS-3,” Biochem. Soc. Trans. 40(part 1):215-218. [cited by applicant]
Wilson, N.S. et al. (Jan. 18, 2011). “An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells,” Cancer Cell 19:101-113. [cited by applicant]
Xu, D. et al. (2000). “In Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies,” Cellular Immunology 200(1):16-26. [cited by applicant]
Xu, J. et al. (Jul. 2000). “Diversity in the CDR3 Region of VH Is Sufficient for Most Antibody Specificities,” Immunity 13:37-45. [cited by applicant]
Yamaji, T. et al. (Feb. 22, 2002). “A Small Region of the Natural Killer Cell Receptor, Siglec-7, Is Responsible for Its Preferred Binding to α2,8-Disialyl and Branched α2,6-Sialyl Residues,” J. Biol. Chem. 277(8):6324-… [cited by applicant]
Yano, H. et al. (Nov. 25, 2009).“Proneurotrophin-3 Is a Neuronal Apoptotic Ligand: Evidence for Retrograde-Directed Cell Killing,” The Journal of Neuroscience 29(47):14790-14802. [cited by applicant]
Ye, J. et al. (Jul. 2013; e-pub. May 13, 2013). “IgBLAST: An Immunoglobulin Variable Domain Sequence Analysis Tool,” Nucleic Acids Research 41:W34-W40. [cited by applicant]
Yelton, D.E. et al. (1995). “Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis,” The Journal of Immunology 155:1994-2004. [cited by applicant]
Yin, F. et al. (Dec. 21, 2009). “Exaggerated Inflammation, Impaired Host Defense, and Neuropathology in Progranulin-Deficient Mice,” J. Exp. Med. 207(1):117-128. [cited by applicant]
Zapata, G. et al. (1995). “Engineering Linear F(ab′)2 Fragments for Efficient Production in [cited by applicant]
Zhou, Q. et al. (Mar. 1, 2014). “Humanized NOD-SCID IL2rg−/− Mice as a Preclinical Model For Cancer Research and its Potential Use For Individualized Cancer Therapies,” Cancer Letters 344(1):13-19. [cited by applicant]
Zhu, Y. et al. (Sep. 15, 2014, e-pub. Jul. 31, 2014). “CSF1/CSF1 R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T Cell Checkpoint Immunotherapy in Pancreatic Cancer Models,” Cancer Researc… [cited by applicant]
International Preliminary Report on Patentability mailed on Mar. 15, 2018 for PCT Application No. PCT/US2016/049032 filed on Aug. 26, 2016, 14 pages. [cited by applicant]
International Search Report and Written Opinion mailed on Jan. 18, 2017 for PCT Application No. PCT/US2016/049032 filed on Aug. 26, 2016, 23 pages. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2019/035990, mailed on Oct. 2, 2019, 10 pages. [cited by applicant]
Chinese Search Report mailed on Feb. 2, 2021 for CN Application No. 201680059071.6 filed on Aug. 26, 2016, 4 pages. [cited by applicant]
Singaporean Search Report and Written Opinion mailed on Dec. 13, 2018 for SG Application No. 11201801640W filed on Feb. 28, 2018, 13 pages. [cited by applicant]
R&D Systems, (2004). “R&D Systems: Catalog Search,” available online at <web.archive.org/web/20040920073524/http://rndsystems.com/asp/c_search.asp?factors=Siglec-7>, 1 page. [cited by applicant]
Rudikoff et al., (1982). “Single amino acid substitution altering antigen-binding specificity,” PNAS USA Immunology, 79:1979-1963. [cited by applicant]
Scott et al., (2007). “Immunocolloidal targeting of the endocytic Siglec-7 receptor using peripheral attachment of Siglec-7 antibodies to poly(lactid-co-glycolide) nanoparticles,” Pharm. Res., 25(1):135-146. [cited by applicant]
UniProt, (2021). “UniProtKB—Q9Y286 (SIGL7 Human), Sialic acid-binding Ig-like lectin Y (SIGLEC7),” Available online at <www.uniprot.org/uniprot/Q9Y286>, 13 pages. [cited by applicant]